Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 1 80 21 versus ORTHO NOVUM 2 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 1 80 21 versus ORTHO NOVUM 2 21.
ORTHO-NOVUM 1/80 21 vs ORTHO-NOVUM 2-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases viscosity of cervical mucus, impeding sperm penetration. Induces endometrial thinning, reducing implantation likelihood.
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing gonadotropin release. Additionally, induces changes in cervical mucus and endometrium.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
One tablet orally once daily for 21 days followed by 7 days off. Each tablet contains norethindrone 2 mg and ethinyl estradiol 0.1 mg.
None Documented
None Documented
Norethindrone terminal half-life: 8-11 hours; Mestranol (ethinyl estradiol pro-drug) terminal half-life: 10-15 hours (metabolite ethinyl estradiol). Clinical context: Steady-state reached in 5-7 days; once-daily dosing maintains therapeutic levels.
Norethindrone: terminal half-life 5-12 hours; ethinyl estradiol: terminal half-life 7-20 hours (enterohepatic recirculation may prolong effect). Steady-state achieved after 5-7 days.
Renal: ~60% (metabolites, primarily glucuronide and sulfate conjugates), Fecal: ~40% (biliary excretion of metabolites). Unchanged drug negligible.
Renal (approx. 60% as metabolites), fecal (approx. 40% as metabolites). Norethindrone and ethinyl estradiol are extensively metabolized; less than 5% excreted unchanged in urine.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive